专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20170015669A1 HETEROARYLAMIDE INHIBITORS OF TBK1 有权
标题翻译： TBK1的异烟肼抑制剂
公开(公告)号：US20170015669A1
公开(公告)日：2017-01-19
申请号：US15123992
申请日：2015-02-12
申请人： Lily KWOK , Mark SABAT , Nicholas SCORAH , Haixia WANG , Steven WOODHEAD , Anthony R. GANGLOFF , TAKEDA PHARMACEUTICAL COMPANY LIMITED , Walter KEUNG
发明人： Walter Keung , Lily Kwok , Mark Sabat , Nicholas Scorah , Haixia Wang , Steven John Woodhead , Anthony R Gangloff
IPC分类号： C07D487/04 , C07D471/04
CPC分类号： C07D487/04 , C07D471/04
摘要： The present invention provides compounds of formula 1: which are useful as inhibitors of TBK-1, pharmaceutical compositions thereof, methods for treatment of conditions associated with TBK1, processes for making the compounds and intermediates thereof.
摘要翻译：其可用作TBK-1的抑制剂，其药物组合物，用于治疗与TBK1相关的病症的方法，用于制备化合物的方法及其中间体。

2. 发明申请

US20130247126A1 METHOD AND DEVICE FOR BUFFERING DATA FOR MULTIPLEXING 有权
标题翻译：用于缓冲多路复用数据的方法和装置
公开(公告)号：US20130247126A1
公开(公告)日：2013-09-19
申请号：US13988856
申请日：2010-11-26
申请人： Jeremy Bennett , Steven Woodhead
发明人： Jeremy Bennett , Steven Woodhead
IPC分类号： H04N21/236
CPC分类号： H04N21/23611 , H04L47/22 , H04L47/2408 , H04L47/29 , H04L47/30 , H04L65/602 , H04N21/23406 , H04N21/23614 , H04N21/23655
摘要： The invention relates to a method and device for buffering data for multiplexing. The invention also relates to a method of multiplexing and to a multiplexer arrangement using the method and device for buffering data for multiplexing. In one embodiment the invention can be applied to the buffering of non-traffic data, such as firmware updates or other supplementary information, before multiplexing the non-traffic data with traffic data, such as television data of television channels, to form a satellite broadcast channel. In embodiments of the invention, non-traffic data for multiplexing is buffered and then read out again for multiplexing at a rate which is a function of buffer fullness. The non-traffic data may be multiplexed with at least one traffic data channel. A multiplexer can view the non-traffic data channel as another multiplexing input and can allocate the available bit rate between the traffic data channels and the non-traffic data accordingly.
摘要翻译：本发明涉及用于缓冲多路复用数据的方法和装置。本发明还涉及使用用于缓冲用于复用的数据的方法和装置的复用方法和多路复用器装置。在一个实施例中，在将非业务数据与诸如电视频道的电视数据的业务数据复用之前，本发明可以应用于非业务数据的缓冲，例如固件更新或其他补充信息，以形成卫星广播渠道。在本发明的实施例中，用于多路复用的非业务数据被缓冲，然后再次读出以以缓冲器充满度的函数的复用。非业务数据可以与至少一个业务数据信道多路复用。多路复用器可以将非业务数据信道视为另一复用输入，并且可以相应地在业务数据信道和非业务数据之间分配可用比特率。

3. 发明申请

US20070082898A1 5 Amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases 审中-公开
公开(公告)号：US20070082898A1
公开(公告)日：2007-04-12
申请号：US10553361
申请日：2004-04-13
申请人： Adrian Gill , Steven Woodhead , Maria Carr
发明人： Adrian Gill , Steven Woodhead , Maria Carr
IPC分类号： A61K31/538 , A61K31/522 , A61K31/52 , A61K31/517 , A61K31/496 , A61K31/4745 , A61K31/4709 , A61K31/4178 , A61K31/416 , C07D417/02 , C07D413/02 , C07D409/02
CPC分类号： C07D409/12 , C07D333/38 , C07D409/14 , C07D417/12 , C07D417/14
摘要： The invention provides the use of a compound for the manufacture of a medicament for the prophylaxis or treatment of a disease state or condition mediated by a p38 MAP kinase; the compound being defined by formula (I): wherein: R1 and R2 are the same or different and each is selected from hydrogen, C1-4 hydrocarbyl, halogen and cyano; X is selected from C═O, C═S, C(═O)NH, C(═S)NH, C(═O)O, C(═O)S, C(═S)O and C(═S)S; R3 is selected from aryl and hetcroaryl groups each having from 5 to 12 ring members, the aryl and heteroaryl groups each being unsubstituted or substituted by one or more substituent groups R7 selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group Ra—Rb wherein Ra is a bond, 0, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc or NRcSO2; and Rb is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 7 ring members, and a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C1-8 hydrocarbyl group may optionally be replaced by O, S, SO, SO2, NRc, X1C(X2), C(X2)X1 or X1C(X2)X1; X1 is O, S or NRc and X2 is ═O, ═S or ═NRc; Rc is hydrogen or C1-4 hydrocarbyl; R4 is a group YR5 or a group R6; Y is is NH, O or S; R5 is selected from (a) carbocyclic and heterocyclic groups having from 3 to 12 ring members; and (b) C1-8 hydrocarbyl groups optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, amino, mono- or di- C1-4 hydrocarbylamino, and carbocyclic and heterocyclic groups having from 3 to 12 ring members, wherein one or more carbon atoms of the C1-8 hydrocarbyl group may optionally be replaced by O, S, SO, SO2, NRc, X1C(X2), C(X2)X1 or X1C(X2)X1, provided that when Y is O, a carbon atom adjacent to the group Y is not replaced by O; and R6 is a heterocyclic group having from 4 to 12 ring members and containing at least one ring nitrogen atom through which R6 is linked to the adjacent carbonyl group; wherein the carbocyclic and heterocyclic groups of substituents R5 and R6 are each unsubstituted or substituted by one or more substituent groups R7 as hereinbefore defined. Also provided are novel compounds, pharmaceutical compositions containing the compounds and methods for their preparation.

4. 发明授权

US09416136B2 Pyrrolopyrimidine compounds and their uses 有权
公开(公告)号：US09416136B2
公开(公告)日：2016-08-16
申请号：US14158358
申请日：2014-01-17
申请人： Gilbert Besong , Christopher Thomas Brain , Clinton A Brooks , Miles Stuart Congreve , Claudio Dagostin , Guo He , Ying Hou , Steven Howard , Yue Li , Yipin Lu , Paul Mortenson , Troy Smith , Moo Je Sung , Steven Woodhead , Wojciech Wrona , Bharat Lagu
发明人： Gilbert Besong , Christopher Thomas Brain , Clinton A Brooks , Miles Stuart Congreve , Claudio Dagostin , Guo He , Ying Hou , Steven Howard , Yue Li , Yipin Lu , Paul Mortenson , Troy Smith , Moo Je Sung , Steven Woodhead , Wojciech Wrona , Bharat Lagu
IPC分类号： A61K31/519 , A61P35/04 , C07D487/04 , C07D487/08
CPC分类号： C07D487/04 , A61K31/519 , C07D487/08
摘要： The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

5. 发明授权

US09078017B2 Method and device for buffering data for multiplexing 有权
标题翻译：用于缓冲多路复用数据的方法和装置
公开(公告)号：US09078017B2
公开(公告)日：2015-07-07
申请号：US13988856
申请日：2010-11-26
申请人： Jeremy Bennett , Steven Woodhead
发明人： Jeremy Bennett , Steven Woodhead
IPC分类号： H04L12/815 , H04L12/801 , H04L12/835 , H04L12/851 , H04L29/06 , H04N7/173 , H04N7/16 , H04J3/24 , H04N21/236 , H04N21/234 , H04N21/2365
CPC分类号： H04N21/23611 , H04L47/22 , H04L47/2408 , H04L47/29 , H04L47/30 , H04L65/602 , H04N21/23406 , H04N21/23614 , H04N21/23655
摘要： The invention relates to a method and device for buffering data for multiplexing. The invention also relates to a method of multiplexing and to a multiplexer arrangement using the method and device for buffering data for multiplexing. In one embodiment the invention can be applied to the buffering of non-traffic data, such as firmware updates or other supplementary information, before multiplexing the non-traffic data with traffic data, such as television data of television channels, to form a satellite broadcast channel. In embodiments of the invention, non-traffic data for multiplexing is buffered and then read out again for multiplexing at a rate which is a function of buffer fullness. The non-traffic data may be multiplexed with at least one traffic data channel. A multiplexer can view the non-traffic data channel as another multiplexing input and can allocate the available bit rate between the traffic data channels and the non-traffic data accordingly.
摘要翻译：本发明涉及用于缓冲多路复用数据的方法和装置。本发明还涉及使用用于缓冲用于复用的数据的方法和装置的复用方法和多路复用器装置。在一个实施例中，在将非业务数据与诸如电视频道的电视数据的业务数据复用之前，本发明可以应用于非业务数据的缓冲，例如固件更新或其他补充信息，以形成卫星广播渠道。在本发明的实施例中，用于多路复用的非业务数据被缓冲，然后再次读出以以缓冲器充满度的函数的复用。非业务数据可以与至少一个业务数据信道多路复用。多路复用器可以将非业务数据信道视为另一复用输入，并且可以相应地在业务数据信道和非业务数据之间分配可用比特率。

6. 发明申请

US20170183352A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES 审中-公开
公开(公告)号：US20170183352A1
公开(公告)日：2017-06-29
申请号：US15231005
申请日：2016-08-08
申请人： Gilbert BESONG , Christopher Thomas BRAIN , Clinton A. BROOKS , Miles Stuart CONGREVE , Claudio DAGOSTIN , Guo HE , Ying HOU , Steven HOWARD , Yue LI , Yipin LU , Paul MORTENSON , Troy SMITH , Moo Je SUNG , Steven WOODHEAD , Wojciech WRONA , Bharat LAGU
发明人： Gilbert BESONG , Christopher Thomas BRAIN , Clinton A. BROOKS , Miles Stuart CONGREVE , Claudio DAGOSTIN , Guo HE , Ying HOU , Steven HOWARD , Yue LI , Yipin LU , Paul MORTENSON , Troy SMITH , Moo Je SUNG , Steven WOODHEAD , Wojciech WRONA , Bharat LAGU
IPC分类号： C07D487/04 , A61K31/519
CPC分类号： C07D487/04 , A61K31/519 , C07D487/08
摘要： The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

7. 发明申请

US20140135312A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES 有权
标题翻译：吡咯啉化合物及其用途
公开(公告)号：US20140135312A1
公开(公告)日：2014-05-15
申请号：US14158358
申请日：2014-01-17
申请人： Gilbert BESONG , Christopher Thomas Brain , Clinton A. Brooks , Miles Stuart Congreve , Claudio Dagostin , Guo He , Ying Huo , Steven Howard , Yue Ll , Yipin Lu , Paul Mortenston , Troy Smith , Moo Je Sung , Steven Woodhead , Wojciech Wrona , Bharat Lagu
发明人： Gilbert BESONG , Christopher Thomas Brain , Clinton A. Brooks , Miles Stuart Congreve , Claudio Dagostin , Guo He , Ying Huo , Steven Howard , Yue Ll , Yipin Lu , Paul Mortenston , Troy Smith , Moo Je Sung , Steven Woodhead , Wojciech Wrona , Bharat Lagu
IPC分类号： C07D487/08 , C07D487/04
CPC分类号： C07D487/04 , A61K31/519 , C07D487/08
摘要： The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
摘要翻译：所公开的化合物涉及蛋白激酶相关病症的治疗和疗法。还需要可用于治疗或预防或改善癌症，移植排斥和自身免疫性疾病的一种或多种症状的化合物。此外，需要使用本文提供的化合物调节蛋白激酶如CDK1，CDK2，CDK4，CDK5，CDK6，CDK7，CDK8和CDK9的活性的方法。

8. 发明申请

US20100105653A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES 有权
标题翻译：吡咯啉化合物及其用途
公开(公告)号：US20100105653A1
公开(公告)日：2010-04-29
申请号：US12545322
申请日：2009-08-21
申请人： Gilbert Besong , Christopher Thomas Brain , Clinton A. Brooks , Miles Stuart Congreve , Claudio Dagostin , Guo He , Ying Huo , Steven Howard , Yue Li , Yipin Lu , Paul Mortenson , Troy Smith , Moo Je Sung , Steven Woodhead , Wojciech Wrona
发明人： Gilbert Besong , Christopher Thomas Brain , Clinton A. Brooks , Miles Stuart Congreve , Claudio Dagostin , Guo He , Ying Huo , Steven Howard , Yue Li , Yipin Lu , Paul Mortenson , Troy Smith , Moo Je Sung , Steven Woodhead , Wojciech Wrona
IPC分类号： A61K31/519 , C07D487/04 , A61K31/551 , C12N5/00
CPC分类号： C07D487/04 , A61K31/519 , C07D487/08
摘要： The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
摘要翻译：所公开的化合物涉及蛋白激酶相关病症的治疗和疗法。还需要可用于治疗或预防或改善癌症，移植排斥和自身免疫性疾病的一种或多种症状的化合物。此外，需要使用本文提供的化合物调节蛋白激酶如CDK1，CDK2，CDK4，CDK5，CDK6，CDK7，CDK8和CDK9的活性的方法。

9. 发明申请

US20060063782A1 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors 审中-公开
标题翻译： 3-芳基甲氧基吡啶及其类似物作为p38映射激酶抑制剂
公开(公告)号：US20060063782A1
公开(公告)日：2006-03-23
申请号：US10519922
申请日：2003-07-03
申请人： Christopher Murray , Michael Hartshorn , Martyn Frederickson , Miles Congreve , Alessandro Padova , Steven Woodhead , Adrian Gill , Andrew Woodhead
发明人： Christopher Murray , Michael Hartshorn , Martyn Frederickson , Miles Congreve , Alessandro Padova , Steven Woodhead , Adrian Gill , Andrew Woodhead
IPC分类号： A61K31/4965 , C07D213/63 , A61K31/44
CPC分类号： C07D213/73 , C07D213/65 , C07D213/74 , C07D213/81 , C07D241/18 , C07D241/20 , C07D241/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D417/12 , C07D417/14 , C07D513/04
摘要： Compounds of the formula (I), wherein: —X═Y— is selected from —CR =CR — and —CR ═N—; R is selected from H, halo, NRR′, NHC(═O)R, NHC(═O)NRR′, NH2SO2R, and C(═O)NRR′; R and R (where present) are independently selected from H, optionally substituted C1-7 alkyl, optionally substituted C5-20 aryl, optionally substituted C3-20 heterocyclyl, halo, amino, amido, hydroxy, ether, thio, thioether, acylamido, ureido and sulfonamino; R is an optionally substituted C5-20 aryl or C5-20 heteroaryl group; and R is selected from R , halo, NHR , C(═O)NHR , OR , SR , NHC(═O)R , NHC(═O)NHR , NHS(═O)R , wherein R is H or C1-3 alkyl (optionally substituted by halo, NH2, OH, SH) are disclosed for use in therapy and for treating diseases ameliorated by inhibiting p38 MAP kinase.
摘要翻译：式（I）的化合物，其中：-X-Y-选自-CR 2 = CR 3 - 和-CR 2 -N-; R 1选自H，卤素，NRR'，NHC（-O）R，NHC（-O）NRR'，NH 2 SO 2 R和C（-O）NRR'; R 2和R 3（如果存在）独立地选自H，任选取代的C 1-7烷基，任选取代的C 5-20芳基，任选取代的C 3-20杂环基，卤素，氨基，酰胺基，羟基，醚，硫代，硫醚，酰氨基，脲基和磺氨基; R 4是任选取代的C 5-20芳基或C 5-20杂芳基; R 5选自R 5，卤素，NHR 5，C（O）NHR 5，OR 5，SR 5，NHC（-O） R 5，NHC（-O）NHR 5，NHS（-O）R 5，其中R 5'是H或C 1-3烷基（任选地被卤素，NH 2，OH ，SH）被公开用于治疗和治疗通过抑制p38 MAP激酶而改善的疾病。

10. 发明申请

US20110152244A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES 有权
标题翻译：吡咯啉化合物及其用途
公开(公告)号：US20110152244A1
公开(公告)日：2011-06-23
申请号：US13060154
申请日：2009-08-20
申请人： Gilbert Besong , Christopher Thomas Brain , Clinton A. Brooks , Miles Stuart Congreve , Claudio Dagostin , Guo He , Ying Huo , Steven Howard , Yue Li , Yipin Lu , Paul Morteson , Troy Smith , Moo Sung , Steven Woodhead , Wojciech Wrona
发明人： Gilbert Besong , Christopher Thomas Brain , Clinton A. Brooks , Miles Stuart Congreve , Claudio Dagostin , Guo He , Ying Huo , Steven Howard , Yue Li , Yipin Lu , Paul Morteson , Troy Smith , Moo Sung , Steven Woodhead , Wojciech Wrona
IPC分类号： C07D487/04 , A61K31/497 , A61K31/519 , A61K31/551 , A61K31/5377 , A61K31/501 , C12N9/99 , A61P35/04 , A61P29/00
CPC分类号： C07D487/04 , A61K31/519 , C07D487/08
摘要： The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
摘要翻译：所公开的化合物涉及蛋白激酶相关病症的治疗和疗法。还需要可用于治疗或预防或改善癌症，移植排斥和自身免疫性疾病的一种或多种症状的化合物。此外，需要使用本文提供的化合物调节蛋白激酶如CDK1，CDK2，CDK4，CDK5，CDK6，CDK7，CDK8和CDK9的活性的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式